|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Liu Z, Bai Y, Xie F, Miao F and Du F:
Comprehensive analysis for identifying diagnostic and prognostic
biomarkers in colon adeno-carcinoma. DNA Cell Biol. Feb 7–2020.Epub
ahead of print. View Article : Google Scholar
|
|
3
|
Rasool S, Kadla SA, Rasool V and Ganai BA:
A comparative overview of general risk factors associated with the
incidence of colorectal cancer. Tumour Biol. 34:2469–2476. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Cutsem E and Nordlinger B: Advanced
colorectal cancer: ESMO clinical practice guidelines for treatment.
Ann Oncol. 21(Suppl 5): v93–v97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH,
Feng H, Zheng MH, Zhao JK and Lu AG: CXCL5 induces tumor
angiogenesis via enhancing the expression of FOXD1 mediated by the
AKT/NF-κB pathway in colorectal cancer. Cell Death Dis. 10:1782019.
View Article : Google Scholar
|
|
6
|
Tomeh MA, Hadianamrei R and Zhao X: A
review of curcumin and its derivatives as anticancer agents. Int J
Mol Sci. 20:E10332019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee SR, Jin H, Kim WT, Kim WJ, Kim SZ,
Leem SH and Kim SM: Tristetraprolin activation by resveratrol
inhibits the proliferation and metastasis of colorectal cancer
cells. Int J Oncol. 53:1269–1278. 2018.PubMed/NCBI
|
|
8
|
Wang JY, Wang Z, Li MY, Zhang Z, Mi C, Zuo
HX, Xing Y, Wu YL, Lian LH, Xu GH, et al: Dictamnine promotes
apoptosis and inhibits epithelial-mesenchymal transition,
migration, invasion and proliferation by downregulating the HIF-1α
and Slug signaling pathways. Chem Biol Interact. 296:134–144. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boldbaatar A, Lee S, Han S, Jeong AL, Ka
HI, Buyanravjikh S, Lee JH, Lim JS, Lee M and Yang Y: Eupatolide
inhibits the TGF-β1-induced migration of breast cancer cells via
downregulation of SMAD3 phosphorylation and transcriptional
repression of ALK5. Oncol Lett. 14:6031–6039. 2017.PubMed/NCBI
|
|
10
|
Avila-Carrasco L, Majano P, Sánchez-Toméro
JA, Selgas R, López-Cabrera M, Aguilera A and González Mateo G:
Natural plants compounds as modulators of epithelial-to-mesenchymal
transition. Front Pharmacol. 10:7152019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu B, Fang TH, Lü GH, Xu HQ and Lu JF:
Beneficial effect of Cyclovirobuxine D on heart failure rats
following myocardial infarction. Fitoterapia. 82:868–877. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu J, Sun D, Gao S, Gao Y, Ye J and Liu P:
Cyclovirobuxine D induces autophagy-associated cell death via the
Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol
Sci. 125:74–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu J, Tan Z, Chen J and Dong C:
Cyclovirobuxine D inhibits cell proliferation and induces
mitochondria-mediated apoptosis in human gastric cancer cells.
Molecules. 20:20659–20668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21(Suppl 7): vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong D, Zhang F, Shao J, Wu L, Zhang X,
Chen L, Lu Y and Zheng S: Curcumin inhibits cobalt chloride-induced
epithelial-to-mesenchymal transition associated with interference
with TGF-β/Smad signaling in hepatocytes. Lab Invest. 95:1234–1245.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Z, Chen Y, An T, Liu P, Zhu J, Yang H,
Zhang W, Dong T, Jiang J, Zhang Y, et al: Nuciferine inhibits the
progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug
signaling pathway. J Exp Clin Cancer Res. 38:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao H, Xu E, Liu H, Wan L and Lai M:
Epithelial-mesenchymal transition in colorectal cancer metastasis:
A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barr S, Thomson S, Buck E, Russo S, Petti
F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW,
Miglarese M, et al: Bypassing cellular EGF receptor dependence
through epithelial-to-mesenchymal-like transitions. Clin Exp
Metastasis. 25:685–693. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pyagay P, Heroult M, Wang Q, Lehnert W,
Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix
repeat containing 1, a novel secreted protein in injured and
diseased arteries, inhibits collagen expression and promotes cell
migration. Circ Res. 96:261–268. 2005. View Article : Google Scholar
|
|
21
|
Ni S, Ren F, Xu M, Tan C, Weng W, Huang Z,
Sheng W and Huang D: CTHRC1 overexpression predicts poor survival
and enhances epithelial-mesenchymal transition in colorectal
cancer. Cancer Med. 7:5643–5654. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim
JT, Kim BY, Lee SJ, Choe YK, Kim DH, et al: Collagen triple helix
repeat containing 1 (CTHRC1) acts via ERK-dependent induction of
MMP9 to promote invasion of colorectal cancer cells. Oncotarget.
5:519–529. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang L, Dai DL, Su M, Martinka M, Li G and
Zhou Y: Aberrant expression of collagen triple helix repeat
containing 1 in human solid cancers. Clin Cancer Res. 12:3716–3722.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang G and Li G: Novel multiple markers
to distinguish melanoma from dysplastic nevi. PLoS One.
7:e450372012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu G, Sengupta PK, Jamal B, Yang HY,
Bouchie MP, Lindner V, Varelas X and Kukuruzinska MA:
N-glycosylation induces the CTHRC1 protein and drives oral cancer
cell migration. J Biol Chem. 288:20217–20227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park EH, Kim S, Jo JY, Kim SJ, Hwang Y,
Kim JM, Song SY, Lee DK and Koh SS: Collagen triple helix repeat
containing-1 promotes pancreatic cancer progression by regulating
migration and adhesion of tumor cells. Carcinogenesis. 34:694–702.
2013. View Article : Google Scholar
|
|
27
|
Chen YL, Wang TH, Hsu HC, Yuan RH and Jeng
YM: Overexpression of CTHRC1 in hepatocellular carcinoma promotes
tumor invasion and predicts poor prognosis. PLoS One. 8:e703242013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Erhardt W, Hebestedt A, Aschenbrenner G,
Pichotka B and Blümel G: A comparative study with various
anesthetics in mice (Pentobarbitone, Ketamine-Xylazine,
Carfentanyl-Etomidate). Res Exp Med (Berl). 184:159–169. 1984.
View Article : Google Scholar
|
|
29
|
Aghajani M, Mansoori B, Mohammadi A,
Asadzadeh Z and Baradaran B: New emerging roles of CD133 in cancer
stem cell: Signaling pathway and miRNA regulation. J Cell Physiol.
234:21642–21661. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lim SH, Jang J, Park JO, Kim KM, Kim ST,
Park YS, Lee J and Kim HC: CD133-positive tumor cell content is a
predictor of early recurrence in colorectal cancer. J Gastrointest
Oncol. 5:447–456. 2014.PubMed/NCBI
|
|
31
|
Kang M, Kim S and Ko J: Roles of CD133 in
microvesicle formation and oncoprotein trafficking in colon cancer.
FASEB J. 33:4248–4260. 2019. View Article : Google Scholar
|
|
32
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in
cancer. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McKay JA, Douglas JJ, Ross VG, Curran S,
Murray GI, Cassidy J and McLeod HL: Cyclin D1 protein expression
and gene polymorphism in colorectal cancer. Aberdeen colorectal
initiative. Int J Cancer. 88:77–81. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar
|
|
35
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J
and Fan S: Polydatin inhibits growth of lung cancer cells by
inducing apoptosis and causing cell cycle arrest. Oncol Lett.
7:295–301. 2014. View Article : Google Scholar
|
|
37
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol (Camb). 3:279–296. 2011. View Article : Google Scholar
|
|
38
|
Liu F, Wang B, Wang J, Ling X, Li Q, Meng
W and Ma J: Oxymatrine inhibits proliferation and migration while
inducing apoptosis in human glioblastoma cells. Biomed Res Int.
2016:17841612016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen Y, Zhao Z, Chen Y, Lv Z, Ding X, Wang
R, Xiao H, Hou C, Shen B, Feng J, et al: An
epithelial-to-mesenchymal transition-inducing potential of
granulocyte macrophage colony-stimulating factor in colon cancer.
Sci Rep. 7:82652017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim BR, Kang MH, Kim JL, Na YJ, Park SH,
Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the
metastasis and angiogenesis of colorectal cancer. Oncol Rep.
36:2601–2608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu J and Thompson CB: Metabolic
regulation of cell growth and proliferation. Nat Rev Mol Cell Biol.
20:436–450. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Y, Liu P, Sun P, Jiang J, Zhu Y, Dong
T, Cui Y, Tian Y, An T, Zhang J, et al: Oncogenic MSH6-CXCR4-TGFB1
feedback loop: A novel therapeutic target of photothermal therapy
in glioblastoma multiforme. Theranostics. 9:1453–1473. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tanaka S, Kobayashi W, Haraguchi M,
Ishihata K, Nakamura N and Ozawa M: Snail1 expression in human
colon cancer DLD-1 cells confers invasive properties without
N-cadherin expression. Biochem Biophys Rep. 8:120–126. 2016.
|
|
45
|
Chen JB, Zhu YW, Guo X, Yu C, Liu PH, Li
C, Hu J, Li HH, Liu LF, Chen MF, et al: Microarray expression
profiles analysis revealed lncRNA OXCT1-AS1 promoted bladder cancer
cell aggressiveness via miR-455-5p/JAK1 signaling. J Cell Physiol.
234:13592–13601. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zheng R, Liang J, Lu J, Li S, Zhang G,
Wang X, Liu M, Wang W, Chu H, Tao G, et al: Genome-wide long
non-coding RNAs identified a panel of novel plasma biomarkers for
gastric cancer diagnosis. Gastric Cancer. 22:731–741. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yin L, Chen Y, Zhou Y, Deng G, Han Y, Guo
C, Li Y, Zeng S and Shen H: Increased long noncoding RNA LASP1-AS
is critical for hepatocellular carcinoma tumorigenesis via
upregulating LASP1. J Cell Physiol. 234:13493–13509. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li YJ, Wang Y and Wang YY: MicroRNA-99b
suppresses human cervical cancer cell activity by inhibiting the
PI3K/AKT/mTOR signaling pathway. J Cell Physiol. 234:9577–9591.
2019. View Article : Google Scholar
|
|
49
|
Yu X, Yuan Z, Yang Z, Chen D, Kim T, Cui
Y, Luo Q, Liu Z, Yang Z, Fan X, et al: The novel long noncoding RNA
u50535 promotes colorectal cancer growth and metastasis by
regulating CCL20. Cell Death Dis. 9:7512018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li Y, Zhang H, Zhao Y, Wang C, Cheng Z,
Tang L, Gao Y, Liu F, Li J, Li Y, et al: A mandatory role of
nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERα-positive
breast cancer cells. Oncogene. 38:808–821. 2019. View Article : Google Scholar
|
|
51
|
Du ZH, Bi FF, Wang L and Yang Q:
Next-generation sequencing unravels extensive genetic alteration in
recurrent ovarian cancer and unique genetic changes in
drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med.
6:638–647. 2018. View Article : Google Scholar :
|
|
52
|
Koveitypour Z, Panahi F, Vakilian M,
Peymani M, Seyed Forootan F, Nasr Esfahani MH and Ghaedi K:
Signaling pathways involved in colorectal cancer progression. Cell
Biosci. 9:972019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Suman S, Kurisetty V, Das TP, Vadodkar A,
Ramos G, Lakshmanaswamy R and Damodaran C: Activation of AKT
signaling promotes epithelial-mesenchymal transition and tumor
growth in colorectal cancer cells. Mol Carcinog. 53(Suppl 1):
E151–E160. 2014. View Article : Google Scholar
|
|
54
|
Yang X, Zheng YT and Rong W: Sevoflurane
induces apoptosis and inhibits the growth and motility of colon
cancer in vitro and in vivo via inactivating Ras/Raf/MEK/ERK
signaling. Life Sci. 239:1169162019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao GX, Ying YX, Weng SQ, Zhang S, Chen
Y, Shen XZ, Dong L and Chen S: CAPS1 promotes colorectal cancer
metastasis via snail mediated epithelial mesenchymal
transformation. Oncogene. 38:4574–4589. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhu D, Zhou J, Zhao J, Jiang G, Zhang X,
Zhang Y and Dong M: ZC3H13 suppresses colorectal cancer
proliferation and invasion via inactivating Ras-ERK signaling. J
Cell Physiol. 234:8899–8907. 2019. View Article : Google Scholar
|
|
57
|
Zheng M, Zhou Q, Liu X, Wang C and Liu G:
CTHRC1 overexpression promotes cervical carcinoma progression by
activating the Wnt/PCP signaling pathway. Oncol Rep. 41:1531–1538.
2019.PubMed/NCBI
|
|
58
|
Wang Y, Lee M, Yu G, Lee H, Han X and Kim
D: CTHRC1 activates pro-tumorigenic signaling pathways in
hepatocellular carcinoma. Oncotarget. 8:105238–105250. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu J, Li W, Liu S, Zheng X, Shi L, Zhang
W and Yang H: Knockdown of collagen triple helix repeat containing
1 (CTHRC1) inhibits epithelial-mesenchymal transition and cellular
migration in glioblastoma cells. Oncol Res. 25:225–232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gu L, Liu L, Zhong L, Bai Y, Sui H, Wei X,
Zhang W, Huang P, Gao D, Kong Y and Lou G: Cthrc1 overexpression is
an independent prognostic marker in gastric cancer. Hum Pathol.
45:1031–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hou M, Cheng Z, Shen H, He S, Li Y, Pan Y,
Feng C, Chen X, Zhang Y, Lin M, et al: High expression of CTHRC1
promotes EMT of epithelial ovarian cancer (EOC) and is associated
with poor prognosis. Oncotarget. 6:35813–35829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Abdifetah O and Na-Bangchang K:
Pharmacokinetic studies of nanoparticles as a delivery system for
conventional drugs and herb-derived compounds for cancer therapy: A
systematic review. Int J Nanomedicine. 14:5659–5677. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li C, Cai G, Song D, Gao R, Teng P, Zhou
L, Ji Q, Sui H, Cai J, Li Q and Wang Y: Development of
EGFR-targeted evodiamine nanoparticles for the treatment of
colorectal cancer. Biomater Sci. 7:3627–3639. 2019. View Article : Google Scholar : PubMed/NCBI
|
